Accelerated AGEing: The Impact of Advanced Glycation End Products on the Prognosis of Chronic Kidney Disease

Elena Dozio,Lara Caldiroli,Paolo Molinari,Giuseppe Castellano, Nicholas Walter Delfrate,Massimiliano Marco Corsi Romanelli, Simone Vettoretti

Antioxidants (Basel, Switzerland)（2023）

Cited 4|Views24

No score

Abstract

Advanced glycation end products (AGEs) are aging products. In chronic kidney disease (CKD), AGEs accumulate due to the increased production, reduced excretion, and the imbalance between oxidant/antioxidant capacities. CKD is therefore a model of aging. The aim of this review is to summarize the present knowledge of AGEs in CKD onset and progression, also focusing on CKD-related disorders (cardiovascular diseases, sarcopenia, and nutritional imbalance) and CKD mortality. The role of AGEs as etiopathogenetic molecules, as well as potential markers of disease progression and/or therapeutic targets, will be discussed.

Translated text

Key words

advanced glycation end products (AGEs),aging,cardiovascular diseases,chronic kidney disease (CKD),inflammation,mortality,pro-oxidant milieu,sarcopenia

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined